| Clinical data | |
|---|---|
| Other names | F14413; 5-Fluoro-methoxyidazoxan |
| Routes of administration | Unspecified |
| Drug class | α2-Adrenergic receptor antagonist or inverse agonist |
| ATC code |
|
| Identifiers | |
| |
| PubChem CID | |
| ChemSpider | |
| Chemical and physical data | |
| Formula | C12H13FN2O3 |
| Molar mass | 252.245 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
F-14413, also known as 5-fluoro-methoxyidazoxan, is an α2-adrenergic receptor antagonist or inverse agonist which was under development for the treatment of Alzheimer's disease and Parkinson's disease in France but was never marketed. It is a derivative of idazoxan. The drug's route of administration was unspecified. It is said to be potent and highly selective as an α2-adrenergic receptor modulator. F-14413 was under development by Pierre Fabre. It reached the preclinical research stage of development prior to its discontinuation. F-14413 was first described in the scientific literature by 2001, while its latest developmental update was in 2003.